000291246 001__ 291246
000291246 005__ 20251024115532.0
000291246 0247_ $$2doi$$a10.1093/neuonc/noae108
000291246 0247_ $$2pmid$$apmid:38912869
000291246 0247_ $$2ISSN$$a1522-8517
000291246 0247_ $$2ISSN$$a1523-5866
000291246 0247_ $$2altmetric$$aaltmetric:164818698
000291246 037__ $$aDKFZ-2024-01338
000291246 041__ $$aEnglish
000291246 082__ $$a610
000291246 1001_ $$00000-0003-0855-6495$$aHegi, Monika E$$b0
000291246 245__ $$aNo benefit from TMZ treatment in GB with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly GB patients.
000291246 260__ $$aOxford$$bOxford Univ. Press$$c2024
000291246 3367_ $$2DRIVER$$aarticle
000291246 3367_ $$2DataCite$$aOutput Types/Journal article
000291246 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1730366714_24810
000291246 3367_ $$2BibTeX$$aARTICLE
000291246 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000291246 3367_ $$00$$2EndNote$$aJournal Article
000291246 500__ $$a2024 Oct 3;26(10):1867-1875
000291246 520__ $$aThe treatment of elderly/ frail patients with glioblastoma is a balance between avoiding undue toxicity, while not withholding effective treatment. It remains debated, whether these patients should receive combined chemo-radiotherapy with temozolomide (RT/TMZ➜TMZ) regardless of the O6-methylguanine DNA methyltransferase gene promoter (MGMTp) methylation status. MGMT is a well-known resistance factor blunting the treatment effect of TMZ, by repairing the most genotoxic lesion. Epigenetic silencing of the MGMTp sensitizes glioblastoma to TMZ. For risk adapted treatment, it is of utmost importance to accurately identify patients, who will not benefit from TMZ treatment.Here, we present a reanalysis of the clinical trials CE.6 and the pooled NOA-08 and Nordic trials in elderly glioblastoma patients that compared RT to RT/TMZ➜TMZ, or RT to TMZ, respectively. For 687 patients with available MGMTp methylation data, we applied a cutoff discerning truly unmethylated glioblastoma, established in a pooled analysis of four clinical trials for glioblastoma, with RT/TMZ➜TMZ treatment, using the same quantitative methylation specific MGMTp PCR assay.When applying this restricted cutoff to the elderly patient population, we confirmed that glioblastoma with truly unmethylated MGMTp derived no benefit from TMZ treatment. In the Nordic/NOA-08 trials RT was better than TMZ, suggesting little or no benefit from TMZ.For evidence-based treatment of glioblastoma patients validated MGMTp methylation assays should be used that accurately identify truly unmethylated patients. Respective stratified management of patients will reduce toxicity without compromising outcome and allow testing of more promising treatment options.
000291246 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000291246 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000291246 650_7 $$2Other$$aMGMT promoter methylation
000291246 650_7 $$2Other$$aelderly/frail GB patients
000291246 650_7 $$2Other$$astratified treatment
000291246 7001_ $$aOppong, Felix B$$b1
000291246 7001_ $$aPerry, James R$$b2
000291246 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b3$$udkfz
000291246 7001_ $$aHenriksson, Roger$$b4
000291246 7001_ $$aLaperriere, Norman J$$b5
000291246 7001_ $$aGorlia, Thierry$$b6
000291246 7001_ $$aMalmström, Annika$$b7
000291246 7001_ $$00000-0002-1748-174X$$aWeller, Michael$$b8
000291246 7001_ $$aNCBTSG$$b9$$eCollaboration Author
000291246 7001_ $$aNOA$$b10$$eCollaboration Author
000291246 7001_ $$aCCTG$$b11$$eCollaboration Author
000291246 7001_ $$aEORTC-BTG$$b12$$eCollaboration Author
000291246 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noae108$$gp. noae108$$n10$$p1867-1875$$tNeuro-Oncology$$v26$$x1522-8517$$y2024
000291246 8564_ $$uhttps://inrepo02.dkfz.de/record/291246/files/noae108.pdf$$yOpenAccess
000291246 8564_ $$uhttps://inrepo02.dkfz.de/record/291246/files/noae108.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000291246 909CO $$ooai:inrepo02.dkfz.de:291246$$popen_access$$popenaire$$pdnbdelivery$$pdriver$$pVDB
000291246 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000291246 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000291246 9141_ $$y2024
000291246 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000291246 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000291246 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000291246 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000291246 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000291246 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000291246 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000291246 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000291246 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000291246 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000291246 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000291246 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000291246 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x0
000291246 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000291246 980__ $$ajournal
000291246 980__ $$aVDB
000291246 980__ $$aUNRESTRICTED
000291246 980__ $$aI:(DE-He78)B320-20160331
000291246 980__ $$aI:(DE-He78)HD01-20160331
000291246 9801_ $$aFullTexts